Innate pharma highlights abstracts selected for the ash annual meeting 2024

Marseille, france--(business wire)-- #anket--regulatory news: innate pharma sa (euronext paris: iph; nasdaq: ipha) (“innate” or the “company”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the tellomak trial and sar443579, sanofi-partnered anket® asset, have been selected for the american society of hematology (ash) annual meeting. “we are proud of the progress being made across our multiple programs, including our lead proprietary asset l.
ASH Ratings Summary
ASH Quant Ranking